Sector News

J&J buys Irish stroke care firm in multimillion euro deal

April 11, 2017
Life sciences

Galway medtech company Neuravi has been taken over by US life sciences giant Johnson & Johnson Codman Neuro business in a landmark deal that gives J&J access to the fast-growing strokecare market.

While details of the price paid for the business have not been disclosed, it is understood that the Neuravi deal is the largest exit for a venture-backed medtech in Europe since 2009. That was the $700 million purchase of a company called Corvalve by Medtronic, suggesting that the Neuravi deal is valued comfortably in the hundreds of millions of euro.

That would deliver a significant payday for the company’s founders and early stage investors.

Removing clots
Neuravi’s EmboTrap device captures and removes clots from blood vessels and restores blood flow. Mechanical retrieval of blood clots has become the industry standard over the past two to three years.
Ischemic stroke, caused by clots in vessels supplying blood to the brain, accounts for 87 per cent of all strokes , reportedly affecting one million patients in Europe every year and a further 700,000 in the United States.

Neuravi’s third-generation device has managed to secure around 30 per cent market share against established rivals Medtronic, Stryker and a newer California company Penumbra, since securing regulatory approval in Europe.

It has recently fully enrolled a pivotal US trial which it expects to deliver results later this year.
It is understood that, under the terms of the deal, Neuravi will continue to operate and expand from its Galway base following the acquisition by Corden’s DePuy Ireland subsidiary.

Management team
Neuravi had raised just over €25 million in funding since its foundation by three former executives at another Galway-based medical device business, MedNova, that was acquired in 2005 by Abbott Laboratories.

The company is led by founders Eamon Brady, who is chief executive, chairman John O’Shaughnessy and chief technical officer David Vale. They will stay with the business under its new ownership.

Abbott was an early investor in the business, which also attracted Fountain Healthcare and Delta Partners in a 2012 series A funding round and top European healthcare investor Life Science Partners in the 2015 series B fundraising.

Fountain Healthcare is the largest single investor in the business, which also features the Western Development Commission and Enterprise Ireland among its investors alongside its founders.

“This is a company that has knocked the ball out of the park,” said Justin Lynch, a partner at Fountain Healthcare Partners which was an early investor in the company. “They have beaten every milestone, earlier and with less money that budgeted, which is almost unheard of in this business.”

By Dominic Coyle

Source: Irish Times

comments closed

Related News

January 22, 2023

Sun Pharma to buy Concert Pharmaceuticals for $576m

Life sciences

Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.

January 22, 2023

Novo Nordisk diabetes pill wins FDA approval for first-line use

Life sciences

The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.

January 22, 2023

Bayer feeling more heat from activist investors, this time from Bluebell

Life sciences

Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.

How can we help you?

We're easy to reach